Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 3, 2025Discover OncologyOpen Access

Gene-edited hematopoietic stem cells for leukemia and lymphoma treatment: a systematic review of preclinical and translational evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

HNHassan NourmohammadiMBMashallah BabashahiMPMohammad Panji

Discussion

Loading...

Member takes

Overview

Systematic review evaluates gene editing, preclinical outcomes, and translational barriers for leukemia and lymphoma.

Key Points

  • Gene-edited hematopoietic stem cells show promising efficacy in treating leukemia and lymphoma, though delivery challenges persist.
  • The systematic review covers 19 studies focusing on methodologies like CRISPR/Cas9 and lentiviral vectors for gene editing.
  • HSCs demonstrate durable tumor clearance and immune reconstitution, yet safety concerns related to gene delivery and engraftment remain.
  • Future research must target improving editing precision and overseeing safety in clinical trials for gene-edited therapies.

Cite This Study

Nourmohammadi et al. (2025) studied this question.

synapsesocial.com/papers/68e02f3cf0e39f13e7fa26c8https://doi.org/10.1007/s12672-025-03529-5
View Full Paper
Ask AI
Bookmark
Share